INTRODUCTION
Epigenetic mechanisms regulate genomic output in normal tissue and are implicated in reprogramming (Maherali et al., 2007; Rideout et al., 2001) . The roles of DNA methylation and histone modifications have been extensively studied in promoter regulation, whereas the significance of nucleosome occupancy is increasingly being recognized (Hinshelwood et al., 2009; Kelly et al., 2010; Lin et al., 2007; Wolff et al., 2010; You et al., 2011) . Distal regulatory regions such as enhancers also play important roles in regulating gene expression, though it has been difficult to identify enhancer/promoter pairs since they can be located at varied distances from transcriptional start sites (TSS) or act in trans (Atchison and Perry, 1988) . Epigenome-wide studies have begun to establish chromatin signatures of active enhancers, which are DNase hypersensitive (Xi et al., 2007) , have a moderate association with p300 (Heintzman et al., 2007; Visel et al., 2009; Wang et al., 2008) , acetylation of histone 3 lysine 27 (H3K27Ac) (Creyghton et al., 2010; Rada-Iglesias et al., 2011) , and a high correlation with histone 3 lysine 4 monomethylation (H3K4me1) (Heintzman et al., 2007 (Heintzman et al., , 2009 Koch et al., 2007) . The presence of H3K4me1 and the absence of H3K27Ac characterize poised enhancers (Creyghton et al., 2010; Rada-Iglesias et al., 2011) , which can be marked by H3K27me3 in embryonic stem cells (ESCs; Rada-Iglesias et al., 2011) . Whether enhancers exist in a similar poised state when paired with promoters carrying only repressive marks (that is, H3K27me3 but not H3K4me3) has not been investigated. The relevance of enhancers paired with inactive genes and their effect on promoter epigenetic signatures is unclear.
In normal somatic cells, genes are typically expressed in a tissue-specific manner or repressed by Polycomb-repressive complex (PRC) and the associated H3K27me3 mark (Gal-Yam et al., 2008) . Interestingly, PRC targets are usually repressed, yet poised for activation in ESCs, carrying the counteracting active (H3K4me3) and repressive (H3K27me3) modifications (Azuara et al., 2006; Bernstein et al., 2006) . Therefore, repression of gene activity by PRC is reversible. Furthermore, various somatic cell types can be reprogrammed by overexpression of some key factors with essential roles in determining cellular identity (Boukamp et al., 1992; Hollenberg et al., 1993; Lassar et al., 1986; Weintraub et al., 1989) . Reprogramming is an active area of interest (Daley et al., 2011) , and it is not yet known how key transcriptional regulators initiate reprogramming, or if enhancers contribute to such events.
To investigate the role of enhancers in detail, we use the tissue-specific autoregulatory MYOD1 gene as a model for understanding epigenetic interactions between enhancer/ promoter pairs. MYOD1 has a well-characterized enhancer located $20 kb upstream of the TSS and contains a minimal core region of 258 base pairs (bp) that is necessary for promoter activity . MYOD1 is expressed in myoblasts but repressed in normal nonmuscle cells by PRC and H3K27me3 (Gal-Yam et al., 2008) . The presence of a welldefined enhancer and a requirement for this transcription factor in muscle lineage determination make MYOD1 an optimal choice for investigation of chromatin structures of an enhancer/ promoter pair in a variety of transcriptional contexts.
In this study, we used a high-resolution nucleosome occupancy and methylome assay (NOMe-seq) to show that the MYOD1 minimal enhancer exhibits a striking nucleosomedepleted region (NDR) that is bordered by H2A.Z containing nucleosomes marked with H3K4me1. This enhancer architecture can be associated with both active and repressed promoter states and is therefore more representative of a permissive state rather than just active enhancers. We found that the PRC-occupied promoter exhibits a multivalent epigenotype in somatic cells and retains some regulatory flexibility, consistent with MYOD1 being in a transcriptionally competent state. In keeping with this observation, the forced expression of exogenous Myod1 results in binding first at the enhancer, followed by chromatin remodeling, causing the formation of a promoter NDR and endogenous expression. Importantly, we also show that reprogramming can be multidirectional. The binding of OCT4 to the MYOD1 enhancer also precedes occupancy at the promoter, which allows for establishment of a bivalent state that is characteristic of stem cells. Thus, in two distinct contexts, the permissive enhancer state orchestrates changes at the promoter through binding of master regulatory factors. We extended our analyses genome-wide and found that permissive enhancers marked by H3K4me1 not only regulate transcriptionally active promoters, but are also paired with PRC-repressed promoters. We observed strikingly similar patterns in several somatic cell types, indicating that this is not a cell-type specific event. Our data suggest that the presence of counteracting epigenetic states at enhancer/promoter pairs ensures the correct tissue specific gene expression patterns of PRC targets, yet transcriptional flexibility is retained. These findings provide insight into the molecular events underlying reprogramming.
RESULTS

MYOD1, a Model for Studying Epigenetic Regulation of an Enhancer/Promoter Pair
We performed detailed epigenetic analyses on the well-characterized regulatory regions of MYOD1 using two cell lines that contained this gene in distinct transcriptional contexts. Quantitative PCR confirmed that MYOD1 is expressed in a human rhabdomyosarcoma cell line (RD) but not normal human fibroblasts (LD419; Figure 1A ). Bisulfite sequencing revealed that the MYOD1 enhancer and promoter were not permanently silenced by DNA methylation in fibroblasts ( Figure 1A ). ChIP assays confirmed enrichment of H3K4me3 ( Figure 1B ) and phosphorylated RNA polymerase II (Pol-IIP; Figure 1C ) in RD cells, as well as Enhancer of Zeste 2 (EZH2; Figure 1D ) and H3K27me3 ( Figure 1E ) in LD419 cells. Thus, the selected cell lines were suitable for studying the active (RD) and PRC-repressed (LD419) contexts of MYOD1.
The MYOD1 Promoter Exhibits a Multivalent Epigenotype When Repressed by PRC in Somatic Cells H2A.Z is associated with key regulatory regions of transcriptionally active and poised regulatory regions genome-wide (Barski et al., 2007; Creyghton et al., 2008) . Consistent with this, H2A.Z was localized to the MYOD1 enhancer/promoter pair in expressing cells (RD; Figure 1F ). We found that H2A.Z remained associated with the MYOD1 promoter even in the presence of EZH2 and H3K27me3 in fibroblasts (LD419; Figure 1F ) and with the enhancer in these cells, though this distal region was devoid of H3K27me3 and EZH2 ( Figures 1D and 1E ). H2A.Z deposition at both proximal and distal gene regulatory regions may therefore serve as one mechanism by which PRC-regulated genes remain permissive.
Previous studies have shown that H3K4me1 is localized to enhancers that act on transcriptionally active genes (Heintzman et al., 2007; Koch et al., 2007; Visel et al., 2009) . We examined H3K4me1 profiles and, as anticipated, detected this modification at the minimal enhancer in MYOD1 expressing cells (RD; Figure 1G) . Unexpectedly, H3K4me1 was also detected at the enhancer in fibroblasts (LD419; Figure 1G ). H3K4me1, but not the H3K4me3 mark characteristic of a bivalent promoter, extended into the TSS of MYOD1 in LD419 cells. Together, these data suggest that the repressed promoter exhibits a multivalent epigenetic signature marked by H2A.Z, H3K4me1 and H3K27me3 in somatic cells. The presence of counteracting histone modifications did not extend to the corresponding enhancer, which was only enriched for marks associated with transcriptional activity.
NDRs Characterize Permissive Enhancers
Nucleosomes are integral to epigenetic regulation, and mapping their location is necessary to accurately view the epigenetic landscape. Taking advantage of the fact that mammalian cells are devoid of GpC methylation, we generate high-resolution nucleosome positioning maps by incubating intact nuclei with M.CviPI, a methyltransferase that recognizes GpC dinucleotides not associated with nucleosomes or tightly bound transcription factors (Kelly et al., 2010; Wolff et al., 2010; You et al., 2011) . This technique provides a digital readout of nucleosome occupancy within individual DNA modules at CpG-rich and CpGpoor regions, while retaining information regarding the endogenous methylation states.
We examined nucleosome occupancy across the MYOD1 promoter and minimal enhancer in active and repressed states (Figure 2) . A prominent NDR was detected in 80% of enhancer modules in cells expressing MYOD1 (RD; Figure 2A , left panel), overlapping exactly with the minimal enhancer and missing at least one nucleosome. Similar to the enhancer, we detected an NDR in approximately 70% of promoter modules in these cells ( Figure 2A, right panel) . Further, we found a highly positioned +1 nucleosome in 80% of promoter modules when an additional 75 bp region downstream of the TSS was included in our analyses (data not shown). Together, these data show using a high-resolution, single-molecule approach that enhancers have open configurations, similar to promoters of active genes.
To determine whether NDRs were characteristic of enhancers regulating PRC-and H3K27me3-repressed promoters ( Figures 1D and 1E ), we examined nucleosome occupancy at the MYOD1 enhancer in fibroblasts (LD419 cells). We found a striking depletion of at least one nucleosome in approximately 40% of enhancer modules in LD419 cells, remarkably similar to actively expressing RD cells (compare Figures 2A and 2B , left panels). The presence of an NDR (Figure 2) , and H2A.Z and H3K4me1 enrichment ( Figures 1F and 1G ), highlights the epigenetic similarities between the MYOD1 enhancer in two distinct transcriptional contexts. Unlike the enhancer, however, every promoter module was occupied by nucleosomes in LD419 cells ( Figure 2B , right panel). Nucleosomes located immediately upstream of the TSS likely contribute to MYOD1 repression in somatic cells. These data show that although promoters repressed by PRC are occupied by nucleosomes, the corresponding enhancer maintains an unexpected open configuration similar to enhancers of transcriptionally active genes. Thus, specific histone modifications and transcription factors, at least that have been mapped to the enhancer in this study, do not predict the activity of the promoter, suggesting that the MYOD1 enhancer may exist in a permissive state in fibroblasts and retain the potential for gene activation in response to the appropriate signals.
Transcriptional Competence Is Determined by the Epigenetic State of the Enhancer
To determine whether the enhancer NDR underlies the permissive nature of PRC-repressed genes and facilitates reprogramming of endogenous MYOD1, we transfected LD419 cells with a plasmid expressing TAP-tagged mouse Myod1 and examined the Myod1 binding kinetics using an anti-TAP antibody. At 6 hr, Myod1 binding was not detected at either the MYOD1 enhancer or promoter ( Figure 3A ). Maximal association of Myod1 at the enhancer occurred by 24 hr, at which time binding was not observed at the MYOD1 promoter (Figure 3B ). These data are consistent with the presence of an NDR only at the enhancer (Figure 2 ), which would physically allow for Myod1 binding. By 48 hr, Myod1 not only associates with the enhancer but is also detected at the TSS of MYOD1 in fibroblasts ( Figure 3C ), suggesting that the promoter had been remodeled and an NDR generated, allowing Myod1 to bind.
In support of this, we detected a newly formed NDR in $34% of individual MYOD1 promoter modules in fibroblasts at 48 hr posttransfection (LD419; Figure 3D , right panel). Interestingly, the proportion of enhancer modules exhibiting an NDR increased only marginally (<10%; Figure 3D , left panel) relative to untransfected cells (compare to Figure 2B , left panel). Despite Myod1 binding to its own regulatory regions (Figures 3B and 3C) and equal transfection (Figure S1A available online), endogenous MYOD1 mRNA expression was only detected when transfected cells were cultured in medium conditioned by RD cells (Figure S1B) , suggesting a requirement for an additional factor that positively induces MYOD1 expression. Identifying specific factors is beyond the scope of this study, though possible candidates include thyroid hormones or insulin-like growth factors (Carnac et al., 1992; Pinset et al., 1988) . Conditioned medium results in additional promoter chromatin remodeling in transfected cells, an increase in DNA modules with an NDR (60%; Figure S1C ) and acquisition of active epigenetic marks ( Figures  S1D-S1F ).
An Enhancer NDR Enables Transcription Factor Binding and Promoter Chromatin Remodeling
To investigate the requirement of the enhancer NDR in reprogramming events, we took advantage of the RKO colorectal cell line, which also does not express MYOD1. In contrast to fibroblasts, the enhancer and promoter of MYOD1 are occupied by nucleosomes in RKO cells (NOME-seq, data not shown), allowing us to determine the mechanistic significance of the permissive chromatin state. Thus, we transfected RKO cells with Myod1-TAP and compared Myod1 binding, as previously. We chose to examine Myod1 occupancy in these cells at 48 hr posttransfection, which was at the time point when we saw maximal Myod1 binding at the MYOD1 enhancer/promoter pair in fibroblasts ( Figure 3C ). Similar to our kinetic study, we see Myod1 associating with the enhancer and promoter of MYOD1 in fibroblasts ( Figure 3E, black bars) . In striking contrast, the MYOD1 enhancer and promoter regions in RKO cells are devoid of Myod1 binding at 48 hr posttransfection ( Figure 3E, gray bars) . Thus, Myod1 does not physically bind to the enhancer nor do we see subsequent binding or chromatin remodeling events at the MYOD1 promoter in these cells ( Figure 3F ).
MYOD1 Gains a Bivalent State after OCT4 Initiates
Reprogramming through the Enhancer Induced pluripotent stem cells (iPSCs) can be generated from somatic cells by forced expression of key transcription factors, such as OCT4 (Maherali et al., 2007; Takahashi et al., 2007; Takahashi and Yamanaka, 2006) . OCT4 association with PRC targets in ESCs correlates with gene inactivity and the presence of a bivalent epigenetic promoter signature (Bernstein et al., 2006) . A bivalent signature (containing both H3K4me3 and H3K27me3) in ESCs allows developmentally important genes to be poised for activation while remaining transcriptionally inactive. Interestingly, the MYOD1 enhancer contains an OCT4 consensus sequence. Critically, no such sequence exists at the promoter, providing a unique system to investigate changes in the enhancer/promoter epigenetic signature. By forcing expression of OCT4 in fibroblasts to initiate processes involved in iPSC generation, we sought to investigate the kinetic events associated with establishing a bivalent state. We transfected LD419 cells with a plasmid expressing OCT4 and examined the binding kinetics using an anti-OCT4 antibody. In mock-transfected cells (0 hr), only a minimal level of OCT4 binding was detected at both the MYOD1 enhancer and promoter ( Figure 4A ). OCT4 occupancy at the enhancer occurred by 24 hr, at which time binding was not enriched at the MYOD1 promoter (Figure 4A ). These data are highly similar to those observed for Myod1 ( Figure 3B ) and consistent with the presence of an NDR only at the enhancer (Figure 2) . By 72 hr, we then detected OCT4 at the MYOD1 promoter ( Figure 4A ). Interestingly, 72 hr after OCT4 overexpression, the H3K4me1 modification at the MYOD1 promoter was replaced by H3K4me3 while maintaining H3K27me3 ( Figures 4B-4D ), indicating that the MYOD1 promoter reverted to a bivalent chromatin signature typical of developmentally important genes in iPSCs and ESCs. There is a lower level of H3K27me3 at both the promoter and enhancer in this state ( Figure 4C , 72 hr), consistent with previous reports that PRC activity is inhibited by the presence of H3K4me3 (Schmitges et al., 2011) and perhaps H3K4me1. We also analyzed the promoter and putative enhancer of GRP78, a constitutively expressed gene, to control for pull-down efficiency ( Figure S2A ). The enhancer was enriched for H3K4me1 in the basal state (0 hr) and was not altered upon OCT4 overexpression (72 hr). As expected, the promoter carried the H3K4me3 modification but was devoid of the repressive H3K27me3 mark even after OCT4 expression. Importantly, only a minimal level of OCT4 was present at the GRP78 enhancer and promoter after 72 hr ( Figure S2A ), demonstrating that the presence of OCT4 is not generalized to all enhancers and promoters. Investigation of nucleosome occupancies showed that the bivalent state remains permissive in that the enhancer still exhibits an NDR, while the promoter is nucleosome occupied ( Figure S2B ). Together, these data offer insight into the molecular events that establish bivalent epigenetic signatures and provides additional evidence that reprogramming is likely initiated through nucleosome-depleted enhancer regions.
Enhancer/Promoter Crosstalk Underlies Reprogramming Events
To understand the mechanisms underlying reprogramming of MYOD1, we next examined the involvement of protein complexes in facilitating enhancer/promoter interactions. To definitively demonstrate enhancer/promoter looping, a chromosome conformation capture assay (3C) can be performed. However, 3C can be unreliable when assessing genomic regions that are as close as 20 kb apart (Dekker, 2006; Dekker et al., 2002; Miele and Dekker, 2009) , as is the case for the MYOD1 enhancer and promoter. Nonetheless, the presence of the cohesin protein complex is consistent with DNA looping and enhancer/promoter interactions (Kagey et al., 2010) . Thus, we measured the presence of the cohesin complex at the MYOD1 enhancer and promoter using an antibody raised against a highly Figure S1 . Bars, mean ± SEM of three biological experiments.
conserved subunit of the complex, RAD21 (Schmidt et al., 2010) . We observed RAD21 binding at the enhancer and promoter regions in expressing cells (RD, black bars; Figure S3A ). An shRNA-targeted knockdown of RAD21 caused a reduction in RAD21 protein ( Figure S3B ) and mRNA levels ( Figure S3C, black bars) . Importantly, this resulted in reduced MYOD1 expression in RD cells ( Figure S3C , green bars), again consistent with the requirement of this complex for DNA looping. We next investigated the necessity for RAD21 in epigenetic reprogramming of MYOD1 in normal human fibroblasts, where MYOD1 is repressed. In LD419 cells a residual amount of RAD21 was bound to the MYOD1 promoter, while the enhancer and inter-regulatory regions were devoid of RAD21 (black bars; Figure 5 ). Following exogenous Myod1 expression, a small amount of RAD21 was detected at the enhancer at 24 hr posttransfection, but promoter occupancy did not change (white bars, Figure 5 ), whereas at 48 hr, RAD21 occupancy increases at both the enhancer and promoter (red bars, Figure 5 ). The presence of cohesin at both the enhancer and promoter is consistent with enhancer/promoter interaction (Kagey et al., 2010) .
Taken together, our data demonstrate that transcription factor binding to the enhancer precedes binding to the promoter, providing evidence that the enhancer NDR underlies a permissive state and directs MYOD1 promoter chromatin remodeling in response to the appropriate signals ( Figures  3D and S1B) , and expression in the presence of the correct factors ( Figure S1A ). The ability of enhancers to drive changes at promoters provides a potential mechanism for reprogramming.
H3K4me1 Marks Enhancers of Transcriptionally Active, as Well as PRC-Repressed, Genes
Epigenome-wide studies have identified correlations between enhancers marked by H3K4me1 and promoter transcriptional activity (Heintzman et al., 2007; Koch et al., 2007; Visel et al., 2009) . However, these studies have not explicitly considered the epigenetic signatures of enhancers paired with inactive promoters. We sought to extend our investigation of MYOD1 and specifically asked whether enhancers marked by H3K4me1 could also be associated with PRC-repressed promoters genome-wide, as indicated by the presence of the H3K27me3 mark.
Previous reports indicate that enhancers located within $10 kb of TSS are statistically linked to promoter activity and that those located upstream of the TSS are more likely to influence transcription (MacIsaac et al., 2010) . Although enhancers may be located several hundreds of kb away (Atchison and Perry, 1988) , additional evidence suggests that enhancers are likely to act on the closest promoter in many situations (Xi et al., 2007) . Therefore, we focused our analyses on those enhancers located in a 10 kb window upstream of the TSS (from À2 to À12 kb) to encompass the same approximate region identified by MacIsaac et al. (2010) , while eliminating the effect of epigenetic marks at adjacent promoters (<2 kb). We probed publicly available ENCODE data sets using the epigenomewide profiles of genomic regions containing either H3K4me1, H3K4me3 or H3K27me3 of the following human cell lines: ESCs (H1), B lymphocytes (GM12878), human mammary epithelial cells (HMEC), normal human epidermal keratinocytes (NHEK) and normal human lung fibroblasts (NHLF) (Kellis et al., 2011) .
We asked whether TSS with promoters marked by either H3K4me3 or H3K27me3 had at least one putative enhancer marked by H3K4me1 within a 10 kb window upstream of the TSS (À2 to À12 kb; Figures 6A and 6B ). As expected, >70% of active promoters with H3K4me3-enriched promoters are paired with enhancers enriched for H3K4me1 across cell types, including ESCs (À2 to À12 kb; left y axis, Figure 6A ). The majority of these enhancers are DNase hypersensitive (i.e., likely depleted of nucleosomes) in normal somatic cells (56%-64%; right y axis, Figure 6A ). We noted that the proportion of DNase hypersensitive enhancers, which are presumably nucleosome depleted, was lower in ESCs (49%) compared to somatic cells. H3K27me3 promoters could also have at least one putative enhancer enriched for H3K4me1 located in this 10 kb window ( Figure 6B ). The percentage of H3K27me3 marked promoters with putative enhancers varied between somatic cell types (27%-57%; Figure 6B , left y axis) and was substantially higher in ESCs (87%; Figure 6B , left y axis). Many enhancers paired with H3K27me3 marked promoters are sensitive to DNase (48%-62%, Figure 6B , right y axis), consistent with nucleosome depletion and as we found with MYOD1 in fibroblasts ( Figure 2B ). Together, these data suggest that H3K4me1 marked enhancers vary in their DNase hypersensitivity and are associated with both active and PRCrepressed promoters.
To extend our findings beyond MYOD1, we examined two additional PRC target genes with validated enhancers PAX6 (Heintzman et al., 2009) and NODAL (Rada-Iglesias et al., 2011) within several ENCODE cell lines. The promoters of PAX6 and NODAL were enriched for H3K27me3, whereas their enhancers exhibited H3K4me1 in the cell types examined ( Figures S4A and S5A) . Examining the chromatin configurations of PAX6 and NODAL in more detail ( Figures S4B and  S5B) , we showed that PAX6 and NODAL were devoid of H3K4me3 and Pol-IIP, yet enriched for EZH2, H3K27me3, H2A.Z, and H3K4me1, consistent with expression (data not shown) in fibroblasts. These data confirm that the generality of our findings can be applied to additional genes and cell types.
Together, H3K4me1 is not a defining mark of ''active'' enhancers alone. Indeed, our data suggest that PRC-repressed promoters can potentially be activated (Figures 3 and 4) and therefore, the enrichment of this histone modification more accurately represents ''permissive'' enhancers that coexist with at least two distinct promoter contexts. 
DISCUSSION
The ability of enhancers to regulate genes in cis and trans has made correlating enhancers with their promoters challenging. Our data emphasize the importance of understanding how enhancer/promoter pairs work together to obtain an accurate view of epigenetic gene regulation. Interestingly, we found that PRC-repressed promoters have permissive enhancers in somatic cells. Conventionally, ''active'' enhancers (H3K4me1) are paired with transcriptionally active promoters (H3K4me3), yet we show that they can also potentially regulate multivalent promoters (H3K27me3/H2A.Z). Therefore, the term ''active'' to describe enhancers characterized by H2A.Z incorporation, H3K4me1 enrichment, and nucleosome depletion may be misleading, and thus we propose the use of ''permissive'' to describe such enhancers. In this way, ''permissive'' describes the epigenetic signature, and also refers to the biological functions of these regulatory regions. Although enhancers can regulate promoters at greater distances or on different chromosomes, Xi et al., (2007) showed that enhancers are likely to act on the closest promoter in many situations. We found that 27%-57% of PRC-repressed promoters have putative enhancers marked by H3K4me1 located À2 to À12 kb upstream of their TSS and at least 48% of them are DNase hypersensitive. Therefore, we suggest that the majority of enhancers found to be nonfunctional in verification assays ($22%; Heintzman et al., 2009 ) might actually represent permissive enhancers that can potentially regulate a PRC occupied promoter.
It is formally possible that the permissive enhancers identified in our epigenome-wide analyses may be activating alternate gene promoters. Thus, we focused on human MYOD1, whose distal enhancer is extremely well characterized and to our knowledge has not been associated with any other gene. This enhancer is critical for MYOD1 activation during development and lineage commitment Goldhamer et al., 1995; Kablar et al., 1999 ). An additional enhancer located $4.8 kb upstream of the TSS also contributes to MYOD1 expression, yet this is restricted to a subset of cells that are already committed (Asakura et al., 1995; Kablar et al., 1997; Tapscott et al., 1992) . The distal enhancer/promoter crosstalk we describe here points to a mechanism for this previous work. Using MYOD1, we show that an NDR at the minimal enhancer region allows reprogramming to be initiated, which occurs in response to signals such as the forced expression of Myod1 in fibroblasts. The nucleosome footprint at the minimal enhancer was only slightly altered in response to Myod1 expression, suggesting that additional chromatin remodeling of enhancer modules is not required for epigenetic crosstalk between the enhancer/promoter pair. In contrast, the endogenous MYOD1 promoter is dramatically remodeled, and an NDR is formed in response to Myod1 expression. It is unclear how the enhancer NDR is established and maintained in the absence of an active promoter. Nucleosome assembly may be inhibited by the binding of an unidentified transcription factor(s) that establishes and maintains the NDR (e.g., You et al., 2011) . These events did not occur when a nucleosome occupies the MYOD1 enhancer and impedes transcription factor binding. Thus, it is possible that an unidentified factor associates with the MYOD1 enhancer in LD419 but not in RKO cells, explaining the difference in chromatin architecture and the inability of these cells to be reprogrammed. Nonetheless, our data highlight the importance of the underlying chromatin state in reprogramming events.
The MYOD1 enhancer also contains an OCT4 consensus sequence, which is not present at the promoter, providing an unequivocal system for investigating changes in the epigenetic signature. Thus, any epigenetic changes that are detected, and the appearance of OCT4 at the promoter (even though there is no binding site), are most likely explained by enhancer/promoter interactions. By forcing OCT4 expression in fibroblasts to initiate processes involved in iPSC generation, we show the kinetic events associated with establishing a bivalent state. As a bivalent state is generated, H3K27me3 is reduced at the enhancer. Whether H3K27me3 is replaced by H3K27Ac is yet to be determined. The replacement of H3K4me1 by H3K4me3 at the promoter, while maintaining H3K27me3, indicates that the MYOD1 promoter reverts to a bivalent chromatin signature in response to forced OCT4 expression. OCT4 may play a direct role in establishing bivalency at MYOD1, although it is also possible that OCT4 expression causes global changes that indirectly lead to this promoter state. A more detailed kinetic study might distinguish between these possibilities.
The OCT4 experiments together with Myod1 show that reprogramming is multidirectional and is ultimately determined by the master transcription factor. Regardless, reprogramming is driven through the nucleosome-depleted enhancer, representing a permissive state and supporting a model that transcription factor binding first to the enhancer is responsible for epigenetic changes at the promoter (Figure 7) .
Our study demonstrates that the MYOD1 promoter is multivalent, carrying epigenetic marks correlated with activation (H3K4me1 and H2A.Z) as well as repression (H3K27me3 and EZH2) in somatic cells. Similar multivalency has been described whereby H2A.Z localizes to H3K27me3-enriched genomic regions in ESCs (Creyghton et al., 2008) . This is comparable to the bivalent signature described in ESCs (H3K4me3 and H3K27me3) (Azuara et al., 2006; Bernstein et al., 2006) , which likely keeps genes poised for induction. The multivalent epigenotype may be generated from a bivalent state in ESCs or generated during lineage commitment. The maintenance of multivalency and the ability to acquire these epigenetic modifications in the correct order may explain why some somatic cells are more suitable for generating iPSCs (Maherali et al., 2007; Takahashi et al., 2007; Takahashi and Yamanaka, 2006) and why some are resistant to reprogramming (Boukamp et al., 1992) .
The specific roles of H2A.Z and H3K4me1 in maintaining a permissive environment are unclear. H2A.Z is localized to the MYOD1 enhancer and promoter in both RD cells and LD419 cells, consistent with its localization to active and poised regulatory regions. The incorporation of H2A.Z may lead to altered nucleosome stability in certain contexts (Jin et al., 2009) , providing a reason for H2A.Z marked nucleosomes at the PRC occupied promoter. The role of H3K4me1 is less clear, and the fact that it marks both the promoter and enhancer of PRC-repressed genes is interesting. Moreover, H3K4me1 is resolved to H3K4me3 at the promoter in expressing cells. The resolution of H3K4me1 to a di-or trimethyl group is not observed at the enhancer, irrespective of the transcriptional state, suggesting that it may have independent roles at distinct gene regulatory regions. It is possible that the H3K4me1 mark acts as a foundation for the addition of methyl groups, resulting in H3K4me2 and H3K4me3 and perhaps priming the promoter for activation. Such dynamic changes have been reported in studies of H3K4me kinetics in developing embryos (Lepikhov and Walter, 2004) . Finally, the presence of H3K4me1 may simply prevent spurious epigenetic activity. It is feasible that enrichment of H3K4me1 interferes with epigenetic silencing A model shows a permissive enhancer is highly comparable to the active enhancer, exemplified by the NDR and H3K4me1 despite the presence of promoter nucleosomes carrying H3K27me3. Reprogramming can be orchestrated from this permissive state by master transcription factors such as Myod1 or OCT4 that access their target through the enhancer. Myod1 overexpression activates a self-regulatory mechanism by binding first to its own enhancer, resulting in recruitment of RAD21 (the cohesin complex), consistent with enhancer/promoter interactions. Promoter changes follow, such as nucleosome eviction and transcription factor occupancy near the TSS. Enhancer-mediated reprogramming is also observed after overexpression of OCT4, resulting in the generation of a bivalent promoter state. Together, these data demonstrate that reprogramming can be forced in multiple directions yet is initiated from the enhancer. NDR, nucleosome-depleted region; small white circle, unmethylated CpG site; small black circle, methylated CpG site; large circle, nucleosome; 4me1 (dark green), H3K4me1; 4me3 (light green), H3K4me3; 27me3 (red), H3K27me3; AcH3, acetylated H3; X, inactive TSS. mechanisms, much like H2A.Z is mutually exclusive with DNA methylation.
Particular emphasis was placed on nucleosome occupancy in our study, utilizing the high-resolution NOME-seq approach, which provides direct evidence that nucleosomes contribute to the repression of PRC target gene promoters in somatic cells, as well as the finding that an NDR is present at the enhancer in opposing transcriptional states. Notably, these data are presented in the context of an enhancer/promoter pair, which we show is necessary to draw accurate conclusions regarding the status of a gene. Our results also indicate that H3K4me1 marked enhancers contribute to the epigenetic regulation of PRC target genes across the genome. Biologically, the presence of an NDR might enable the enhancer to respond to activating signals, which triggers promoter chromatin remodeling and causes a promoter NDR to form. This may explain how transcription factors gain access to their targets and how repressive chromatin states impede reprogramming events. In fact, our data demonstrate that the enhancer of PRC target genes may allow these loci to remain permissive in somatic cells, retaining epigenetic plasticity and initiating reprogramming.
EXPERIMENTAL PROCEDURES
Cell Culture
The RD and colorectal (RKO) cell lines were obtained from the American Type Culture Collection (ATCC) and cultured under recommended conditions. A normal human fibroblast cell line (LD419) was generated in our laboratory and cultured in McCoy's 5A medium supplemented with 20% FBS, 100 U/ml penicillin and 100 mg/ml streptomycin at 37 C and 5% CO 2 .
RNA Isolation and Quantitative PCR Analysis RNA was isolated using Trizol reagent, digested with DNase I, and reverse transcribed (iScript, BioRad). cDNA was amplified using the CFX96 Realtime PCR detection system (BioRad) and SYBR Fast qPCR Mix (Kapa Biosystems) under the following conditions: 95 C for 3 min, followed by 45 cycles of 95 C for 3 s then 60 C for 30 s. A melt curve analysis was performed (60 C -95 C, rising by 1 C every 5 s). Oligonucleotides are listed in Table S1 . Analyses were conducted in parallel using human GAPDH for normalization. A standard curve was generated for each primer set to correlate threshold (Ct) values to copy number.
Nucleosome Occupancy and Methylome Sequencing Nuclei were extracted as described previously (Schreiber et al., 1989) . Briefly, cells were trypsinized and centrifuged for 3 min at 500 3 g, then washed in ice-cold PBS and resuspended in 1 ml ice-cold nuclei buffer (10 mM Tris [pH 7.4], 10 mM NaCl, 3 mM MgCl 2 , 0.1 mM EDTA, and 0.5% NP-40, plus protease inhibitors) per 5 3 10 6 cells and incubated on ice for 5 min. Nuclei were recovered by centrifugation at 900 3 g for 3 min and washed in nuclei wash buffer (10 mM Tris [pH 7.4], 10 mM NaCl, 3 mM MgCl 2 , and 0.1 mM EDTA containing protease inhibitors). Freshly prepared nuclei (2 3 10 5 cells) were resuspended in 13 M.CviPI reaction buffer (NEB), then treated with 200 U of M.CviPI (NEB) in 15 ml 103 reaction buffer, 45 ml 1M sucrose, and 0.75 ml SAM in a volume of 150 ml. Reactions were quenched by the addition of an equal volume of Stop Solution (20 nM Tris-HCl [pH 7.9], 600 mM NaCl, 1% SDS, 10 mM EDTA, 400 mg/ml Proteinase K) and incubated at 55 C overnight. DNA was purified by phenol/chloroform extraction and ethanol precipitation. Bisulfite conversion was performed using the Epitect Bisulfite Kit (QIAGEN). Molecules were cloned using the Topo TA Kit (Invitrogen), both according to the manufacturers' instructions.
Transfections
The Myod1-TAP and OCT4 plasmids were obtained from Addgene. Transfections were performed using Lipofectamine LTX and Plus Reagent (Invitrogen) according to the manufacturers' instructions. Mock transfections served as negative controls. Transfections were performed in 10 cm tissue culture plates using 12.5 mg of Myod1-TAP or OCT4 plasmid DNA. For conditioned medium experiments, RD cells (2 3 10 6 ) were cultured for 24 hr in McCoy's 5A supplemented with 20% FBS, without penicillin/streptomycin. Medium was sterile filtered to remove debris and detached cells. Medium was added to LD419 cells 6 hr posttransfection and replaced at 24 hr. Cells were harvested as required.
Chromatin Immunoprecipitation
Chromatin immunoprecipitation (ChIP) assays were performed as previously (Kelly et al., 2010) . For assays using anti-H3K4me1, anti-TAP, and anti-RAD21 antibodies, nuclei were purified after formaldehyde crosslinking, then resuspended in SDS lysis buffer before sonication. Antibodies (10 mg) used for ChIP experiments included histone H3 (#ab1791, Abcam), H2A.Z (#ab4174, Abcam), H3K4me1 (#39298, Active Motif), H3K4me3 (#39160, Active Motif), H3K27me3 (#07-360, Millipore), EZH2 (#39639, Active Motif), RNA Polymerase II (phosphorylated) (#ab24758, Abcam), RNA Polymerase II (#ab817, Abcam), TAP (#CAB1001, Open Biosystems), RAD21 (#ab992, Abcam), and CD8 (#sc-32812, Santa Cruz). Quantitative PCR (qPCR) for ChIP was performed as described for mRNA analyses. Oligonucleotides are listed in Table S1 . For each PCR, DNA standards were included for quantitation. Samples were also immunoprecipitated with a nonspecific antibody (CD8) to control for background enrichment. Immunoprecipitated DNA was calculated as a percentage of input DNA.
Epigenome-wide Analyses of Enhancer/Promoter Pairs
From the UCSC Genome Browser (Raney et al., 2011) , we downloaded the ENCODE epigenome-wide modification profiles of H4K3me1, H4K3me3, and H3K27me3 for five cell lines: ESCs (ES), B lymphocytes (GM12878), human mammary epithelial cells (HMEC), NHEK, and NHLF (Kellis et al., 2011) . For the same cell lines, we also downloaded genome-scale mapping of DNase I sensitivity data (Stamatoyannopoulos et al., 2006) . We used the UCSC KnownGene database to define the transcriptional start site (TSS). For 66,803 KnownGenes, we defined putative promoter regions to be ±500 bases around the TSS, and putative enhancer regions to be -(X + 10 kb) or -(X + 1 kb) upstream of the TSS (where X = 2 kb, 3 kb, ., 10 kb). For each cell line, we counted the number of KnownGenes with either H4K3me3 or H3K27me3 at the promoter, and the percentage of those with H4K3me1 at the enhancer, respectively. We also determined the proportion of H3K4me1 marked enhancers that exhibit DNase hypersensitivity. 
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